Recurrent Bacterial Vaginosis and Yeast Infections: Prevention, Partner Treatment and Pregnancy

Evidence reviewed: 8 November 2026. Repeated episodes of bacterial vaginosis (BV) or vulvovaginal candidiasis (VVC, vaginal yeast infection) can be frustrating, but they should not automatically be treated as one recurring condition. BV reflects a change in the vaginal bacterial community; VVC is symptomatic inflammation caused by Candida species. Their diagnosis, prevention and long-term treatment differ. Importantly, a 2025 randomized trial and 2026 specialist recommendations have changed discussion about treating selected male partners to prevent BV recurrence, although this remains a clinician-directed strategy rather than routine self-prescribing [1–5].

What counts as a recurrent infection?

Recurrent BV refers to repeated symptomatic episodes after successful treatment. There is no single uniformly used numerical threshold across all guidelines, though clinicians often investigate patients with multiple confirmed episodes within a year. The CDC notes that BV recurrence is common and that maintenance or suppressive regimens may be appropriate for selected people with multiple recurrences [1].

Recurrent vulvovaginal candidiasis (RVVC) is defined by the CDC as three or more symptomatic episodes within less than one year. Recurrent Candida symptoms may involve C. albicans, other species such as C. glabrata, or conditions that imitate yeast infection [2].

Before starting long-term medicine, it is important to confirm which condition is recurring, because repeated itching, odor or discharge can have different causes at different times.

Why might bacterial vaginosis return?

BV involves a shift from a Lactobacillus-dominant vaginal community toward diverse anaerobic bacteria and, often, a persistent bacterial biofilm. Associations include new or ongoing sexual exposures, lack of condom use, douching and individual microbial factors [1]. Recurrence does not prove a person has poor hygiene or was unfaithful. BV may return even after the correct recommended antimicrobial course.

New research indicates that some BV-associated organisms may be exchanged within sexual partnerships, helping explain why treating the vaginal microbiome alone sometimes fails. This does not convert every BV episode into a single-organism STI or establish that partners must always receive antibiotics [3,4].

Why might yeast symptoms return?

Some people experience recurrent symptomatic C. albicans infection, while others have non-albicans Candida that responds differently to usual azole medicines. Contributing factors can include diabetes with poor glycemic control, immunosuppression or recent antibiotic exposure, but many people have no obvious risk factor. Persistent “yeast” symptoms may instead reflect contact dermatitis, vulvodynia, vulvar inflammatory disease, BV or another condition [2].

Candida colonization alone is not an indication for treatment. Some healthy people have positive vaginal Candida tests without symptoms, and repeatedly treating those results can cause unnecessary irritation or drug exposure [2].

BV and yeast: clues and tests

Feature Recurrent BV Recurrent VVC
Common symptoms Thin uniform discharge, sometimes fishy odor; itching may be mild Prominent itch, soreness, inflammation; discharge variable
Vaginal pH Frequently above 4.5 Usually below 4.5, although mixed infections occur
Diagnostic evidence Amsel clinical findings, Nugent Gram stain or validated symptomatic-patient molecular tests Wet mount/KOH microscopy, culture or validated testing, including species identification in recurrent cases
First-line drug class Metronidazole or clindamycin Topical or appropriate oral azole antifungals
Longer-term strategy Selected suppressive metronidazole regimens or newer partner-treatment approaches Culture-guided induction and selected suppressive fluconazole if safe and appropriate

Because trichomoniasis, cervicitis and other STIs can cause similar discharge and odor, clinicians may recommend testing for trichomonas, chlamydia, gonorrhea or other infections according to the person’s symptoms and exposure history. New pelvic pain, fever, pregnancy-related bleeding or systemic illness requires timely assessment [1,2].

Initial treatment for symptomatic BV

The CDC lists appropriate first-line treatment options such as oral metronidazole 500 mg twice daily for seven days, metronidazole 0.75% vaginal gel once daily for five days, or clindamycin 2% vaginal cream for seven days [1]. These are reference regimens and not a prescription for self-treatment; the right choice depends on pregnancy, allergies, tolerability and medical history.

After one recurrence, the CDC allows retreatment with the same recommended regimen or another appropriate regimen. Additional assessment is important when symptoms repeatedly return or never fully resolve. Do not assume all discharge indicates the same diagnosis each time.

Suppressive treatment for repeated BV episodes

For multiple confirmed BV recurrences, the CDC describes clinician-directed approaches such as metronidazole 0.75% vaginal gel twice weekly for more than three months. This can reduce recurrence while treatment continues, but benefit may diminish after it is stopped [1]. Other sequential combination regimens have been studied for difficult cases, but they require specialist counseling and careful selection.

Vaginal boric acid appears in some specialist-directed multi-step strategies for refractory BV, but is not first-line therapy, must never be swallowed, and should not be used during pregnancy or without professional guidance. Boric acid can be toxic if ingested and can cause local irritation. Products marketed as “vaginal detox” are not evidence-based substitutes for diagnosis and treatment [1,2].

2025 trial: does treating the male partner reduce recurrent BV?

The StepUp randomized trial, published in the New England Journal of Medicine in March 2025, studied couples in monogamous relationships where the woman had BV. Women received recommended treatment; men in the intervention group received a seven-day oral and topical antibiotic regimen. Within 12 weeks, recurrent BV occurred in 24 of 69 women (35%) when their male partners were treated, compared with 43 of 68 (63%) in the standard-care group [3].

This is important evidence, but the findings come from a particular trial population and combination regimen. They do not prove that treating every asymptomatic partner is appropriate or that antibiotics should be shared or prescribed without assessment. The older CDC 2021 guidelines had stated that routine partner treatment was not recommended, based on earlier largely negative trials [1]. The newer trial means that blanket advice should be reassessed in the light of up-to-date specialist guidance.

What changed in 2026 partner-treatment guidance?

A 2026 International Society for the Study of Vulvovaginal Disease (ISSVD) update and New York State Department of Health AIDS Institute guidance discuss offering or considering concurrent partner treatment for selected patients with recurrent BV, following appropriate shared decision-making [4,5]. The studied male regimen included oral metronidazole plus topical clindamycin applied to penile skin; it requires clinician evaluation of both partners and counseling about adherence, interactions and adverse effects.

Partner treatment is not universal routine practice in every country, and the relevant care pathway may differ according to national guidelines, whether partners are male or female, and the available evidence. People with recurring BV can ask a sexual-health clinician whether partner-inclusive care is suitable rather than automatically assuming no partner treatment is ever useful.

Does recurrent yeast infection require partner treatment?

Generally no. Uncomplicated vulvovaginal candidiasis is not usually acquired through sexual intercourse, and the CDC does not support routine treatment of asymptomatic sex partners to prevent yeast recurrence [2]. A partner with their own genital symptoms should be clinically assessed; sharing antifungals or antibiotics is not appropriate.

This important difference separates the emerging evidence on BV partner management from ordinary Candida treatment.

How should recurrent Candida infection be treated?

For recurrent C. albicans VVC, the CDC recommends a longer induction phase before maintenance—for example, seven to fourteen days of topical azole therapy or fluconazole doses on days 1, 4 and 7 in appropriate nonpregnant patients—followed by fluconazole weekly for six months when suitable [2].

This is not a standard regimen for every person with vaginal itching. Oral fluconazole has drug interactions, liver safety issues, reproductive precautions and potential QT-related risks. Species identification and susceptibility testing may be important when symptoms persist or recur despite treatment. Suppressive therapy frequently controls episodes but is not always permanently curative [2].

Non-albicans Candida and resistant infections

Some recurrent yeast infections involve C. glabrata or another non-albicans species. These organisms may respond poorly to common single-dose fluconazole regimens, so the CDC recommends confirming the organism and considering longer, appropriate non-fluconazole azole therapy in selected cases [2]. Persistent culture-positive infection may justify susceptibility testing and specialist management.

The CDC describes intravaginal boric acid as one possible specialist-directed option after recurrence of selected non-albicans VVC, but it must never be taken by mouth and should not be used during pregnancy. The existence of a guideline option does not make boric acid a safe general-purpose product for every vaginal symptom [2].

Pregnancy changes treatment decisions

Symptomatic BV during pregnancy should be assessed and treated with an appropriate regimen because it is associated with adverse pregnancy outcomes; the CDC reports that metronidazole use has a low risk based on available human pregnancy data [1].

For vulvovaginal candidiasis during pregnancy, the CDC recommends topical azoles used for seven days. Oral fluconazole should not be used routinely because of associations with miscarriage and congenital anomalies [2]. Avoid boric acid in pregnancy, and seek a pregnancy-aware clinical assessment before using any recurrence regimen.

What can help prevent recurrent symptoms?

  • Avoid vaginal douching, fragranced internal washes and unverified “cleanses” that can irritate tissue.
  • Use condoms when appropriate, especially in the context of STI risk or discussions about BV recurrence.
  • Complete prescribed therapy and return if symptoms fail to improve.
  • Discuss diabetes screening or improved glycemic management if relevant to recurrent yeast infections.
  • Review medication exposures such as repeated antibiotics or immunosuppressants when clinically relevant.
  • Seek repeat testing and Candida species identification after recurrent or difficult yeast symptoms.
  • Discuss sexual-health assessment and partner-inclusive care for repeated BV under up-to-date local guidance.
  • Avoid unnecessary long-term suppression or supplements without a confirmed diagnosis and treatment plan.

Are probiotics proven to prevent BV or yeast recurrence?

Some specific vaginal Lactobacillus products are being researched for BV recurrence, including promising strain-specific trials, but the CDC did not endorse ordinary marketed probiotics as substitutes or routine adjuncts to BV treatment in its existing guidelines [1]. Evidence varies by strain, formulation and clinical setting. Similarly, the CDC found no substantial evidence supporting probiotic treatment of VVC [2].

Consuming plain yogurt as food is generally different from inserting yogurt or other products intravaginally; the latter is not established treatment and can worsen irritation. No supplement has been proven to correct all vaginal microbiome abnormalities.

When should a clinician investigate beyond BV or yeast?

Persistent symptoms after adequate treatment deserve reassessment rather than automatic repetition of pills. Possibilities include trichomoniasis or other STIs, desquamative inflammatory vaginitis, aerobic vaginitis, vulvar eczema, lichen sclerosus, contact dermatitis or a mixed infection. A clinician may perform pelvic and vulvar examination, pH testing, wet mount, cultures or molecular panels selected for symptoms.

Seek urgent care for fever, severe pelvic pain, vomiting, faintness, pregnancy-associated bleeding or systemic illness. Vaginal symptoms accompanied by pelvic pain may suggest pelvic inflammatory disease or another emergency.

Frequently asked questions

Can BV recur after I complete seven days of metronidazole?

Yes. Recurrence is common even with an appropriate course. Repeat testing and selected suppressive or partner-related approaches may be needed [1,3].

Is treating male partners now recommended for all BV cases?

No. A 2025 trial supports concurrent treatment in a particular group, and 2026 specialty guidance addresses selected recurrent cases. Clinical assessment and local guidance are essential [3–5].

Does a positive yeast test always mean an infection needs treatment?

No. Asymptomatic Candida colonization often requires no therapy [2].

How many yeast episodes count as recurrent?

The CDC uses three or more symptomatic VVC episodes in less than one year [2].

Is long-term fluconazole appropriate during pregnancy?

No. Pregnancy requires a different care plan, generally involving topical azoles for seven days when VVC is confirmed [2].

Can I swallow vaginal boric acid capsules?

Never. Boric acid is toxic if swallowed and is inappropriate during pregnancy; discuss any proposed use with a clinician.

Key takeaways

Confirm the cause of recurrent vaginal symptoms before extending treatment. Recurrent BV and recurrent VVC need different tests and medicines. The 2025 StepUp trial and 2026 specialty guidance support considering male-partner treatment for selected recurrent BV cases, while routine partner treatment is not supported for yeast infection. Pregnancy and treatment resistance demand particular care.

For first episodes, symptom differences, vaginal pH and standard treatment, read our companion BV versus yeast infection diagnosis and treatment guide.

References

  1. Centers for Disease Control and Prevention. Bacterial vaginosis: STI treatment guidelines. CDC; accessed 8 Nov 2026.
  2. Centers for Disease Control and Prevention. Vulvovaginal candidiasis: STI treatment guidelines. CDC; accessed 8 Nov 2026.
  3. Vodstrcil LA, Plummer EL, Fairley CK, et al. Male-partner treatment to prevent recurrence of bacterial vaginosis. N Engl J Med. 2025;392:947–957. doi:10.1056/NEJMoa2405404. PubMed.
  4. International Society for the Study of Vulvovaginal Disease. Partner treatment in women with bacterial vaginosis: update to ISSVD recommendations. Sex Transm Infect. 2026.
  5. New York State Department of Health AIDS Institute. Partner treatment to prevent recurrent bacterial vaginosis: clinical guidance. 2026.

Medical disclaimer: Educational information only. Recurrent vaginal symptoms, possible STIs, pregnancy or treatment resistance need clinician evaluation. Never share antibiotics, self-prescribe partner treatment, take boric acid by mouth or use prolonged antifungal suppression without appropriate medical supervision.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *